Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.

Literature DB >> 26017507

Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.

P Barbanti¹, G Egeo, L Fofi, C Aurilia, S Piroso.

Abstract

Chronic migraine is a severely disabling headache evolving from episodic migraine as a result of different transforming factors and characterized by atypical pain modulation and peripheral and central sensitization. Discovered by serendipity, onabotulinum toxin A (BoNT-A) represents the only drug specifically approved for CM prophylaxis. According to the dominant opinion, BoNT-A acts peripherally, impairing the exocytosis of neuropeptide and neurotransmitter and the delivery of receptors and ion channels on the cell surface of peripheral trigeminal endings, thereby indirectly reducing central sensitization. However, it is not excluded that BoNT-A has also a central antinociceptive action, probably associated with an enhanced opioidergic and GABA-ergic transmission. This review discusses the rationale for use of BoNT-A in CM including its mechanisms of action and molecular targets and provides suggestions for a more tailored BoNT-A prophylaxis in patients with CM.

Entities: Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26017507 DOI： 10.1007/s10072-015-2195-0

Source DB: PubMed Journal: Neurol Sci ISSN： 1590-1874 Impact factor: 3.307

39 in total

1. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors: M J Welch; J R Purkiss; K A Foster
Journal: Toxicon Date: 2000-02 Impact factor: 3.033

2. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.

Authors: Parisa Gazerani; Sammy Au; Xudong Dong; Ujendra Kumar; Lars Arendt-Nielsen; Brian E Cairns
Journal: Pain Date: 2010-08-21 Impact factor: 6.961

3. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors: S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal: Cephalalgia Date: 2010-03-17 Impact factor: 6.292

4. Stages of regulated exocytosis.

Authors: T F Martin
Journal: Trends Cell Biol Date: 1997-07 Impact factor: 20.808

5. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

Authors: V Drinovac; L Bach-Rojecky; Z Lacković
Journal: J Neural Transm (Vienna) Date: 2014-01-14 Impact factor: 3.575

6. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons.

Authors: Judy L Morris; Phillip Jobling; Ian L Gibbins
Journal: Am J Physiol Heart Circ Physiol Date: 2002-08-29 Impact factor: 4.733

7. Ectopic vesicular neurotransmitter release along sensory axons mediates neurovascular coupling via glial calcium signaling.

Authors: Anne Thyssen; Daniela Hirnet; Hartwig Wolburg; Günther Schmalzing; Joachim W Deitmer; Christian Lohr
Journal: Proc Natl Acad Sci U S A Date: 2010-08-09 Impact factor: 11.205

8. A(2a) adenosine receptor mediates PKA-dependent glutamate release from synaptic-like vesicles and Ca(2+) efflux from an IP(3)- and ryanodine-insensitive intracellular calcium store in astrocytes.

Authors: Takeshi Kanno; Tomoyuki Nishizaki
Journal: Cell Physiol Biochem Date: 2012-11-16

9. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.

Authors: Patrick M Grogan; Maria Victoria Alvarez; Lyell Jones
Journal: Headache Date: 2012-11-05 Impact factor: 5.887

10. Botulinum neurotoxin A and neurotoxin E cleavage products of synaptosome-associated protein of 25 kd exhibit distinct actions on pancreatic islet beta-cell Kv2.1 channel gating.

Authors: Yan He; Chadwick L Elias; Ya-Chi Huang; Xiaodong Gao; Yuk-Man Leung; Youhou Kang; Huanli Xie; John A Chaddock; Robert G Tsushima; Herbert Y Gaisano
Journal: Pancreas Date: 2008-01 Impact factor: 3.327

7 in total

1. Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis.

Authors: Emmanouil V Dermitzakis; Michail Vikelis; George S Vlachos; Andreas A Argyriou
Journal: Toxins (Basel) Date: 2022-04-21 Impact factor: 5.075

Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.

1. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

2. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.

3. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

4. Stages of regulated exocytosis.

5. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

6. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons.

7. Ectopic vesicular neurotransmitter release along sensory axons mediates neurovascular coupling via glial calcium signaling.

8. A(2a) adenosine receptor mediates PKA-dependent glutamate release from synaptic-like vesicles and Ca(2+) efflux from an IP(3)- and ryanodine-insensitive intracellular calcium store in astrocytes.

9. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.

10. Botulinum neurotoxin A and neurotoxin E cleavage products of synaptosome-associated protein of 25 kd exhibit distinct actions on pancreatic islet beta-cell Kv2.1 channel gating.

1. Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis.

2. Association of Upper Eyelid Ptosis Repair and Blepharoplasty With Headache-Related Quality of Life.

3. Anatomical Regional Targeted (ART) BOTOX Injection Technique: A Novel Paradigm for Migraines and Chronic Headaches.

4. Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans.

5. The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches.

6. Acupoint injection of onabotulinumtoxin A for migraines.

Review 7. Pressure pain thresholds over the cranio-cervical region in headache: a systematic review and meta-analysis.